Gustafsson B, Axelsson B, Gustafsson B, Christensson B, Winiarski J
Department of Paediatrics, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden.
Pediatr Hematol Oncol. 2001 Dec;18(8):497-508. doi: 10.1080/088800101753328466.
In previous studies the authors have found increased expression of p53 and MDM2 proteins in leukemic cells in a majority of children eligible for bone marrow transplantation (BMT) due to relapse or prognostically unfavorable features. In this study the immunohistochemical expression of p53, MDM2, and p21Cip1 was investigated in bone marrow samples from the time of diagnosis in 30 children with acute lymphoblastic leukemia (ALL) surviving disease-free at least 5 years. This group was compared with 15 advanced ALL patients, admitted for BMT. In 7 of the BMT patients orginal diagnostic marrow samples were also available for analysis. Four out of 30 ALL patients in the relapse-free group expressed p53 in the original leukemic cell population, while 8/15 advanced ALL patients did before BMT (p = .014). Four out of 30 cases in the relapse-free group expressed MDM2, while 10/15 in the BMT group did (p = .0011). In retrospect, MDM2 overexpression at the time of diagnosis was also more common (p = .0098) in the BMT group as well as p53 overexpression (p = .054) compared to nonrelapsed patients.
在先前的研究中，作者发现，由于复发或预后不良特征而适合进行骨髓移植（BMT）的大多数儿童白血病细胞中，p53和MDM2蛋白表达增加。在本研究中，对30例至少无病存活5年的急性淋巴细胞白血病（ALL）儿童诊断时骨髓样本中p53、MDM2和p21Cip1的免疫组化表达进行了研究。该组与15例接受BMT的晚期ALL患者进行了比较。在7例BMT患者中，原始诊断骨髓样本也可用于分析。无复发组30例ALL患者中有4例在原始白血病细胞群体中表达p53，而15例晚期ALL患者中有8例在BMT前表达（p = 0.014）。无复发组30例中有4例表达MDM2，而BMT组15例中有10例表达（p = 0.0011）。回顾性分析，与未复发患者相比，BMT组诊断时MDM2过表达也更常见（p = 0.0098）以及p53过表达（p = 0.054）。
